SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals reports 17% rise in Q4 consolidated net profit

10 May 2024 Evaluate

Alembic Pharmaceuticals has reported results for fourth quarter (Q4) and year ended March 31, 2024.

The company has reported 54.64% rise in its net profit at Rs 201.87 crore for the quarter under review as compared to Rs 130.54 crore for the same quarter in the previous year. Total income of the company increased by 13.19% at Rs 1,481.78 crore for Q4FY24 as compared Rs 1,309.08 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 16.78% rise in its net profit at Rs 178.21 crore for fourth quarter ended March 31, 2024 as compared to Rs 152.60 crore for the same quarter in the previous year. Total income of the company increased by 8.05% at Rs 1,520.57 crore for Q4FY24 as compared Rs 1,407.34 crore for the corresponding quarter previous year.

For the year ended March 31, 2024, the company has reported 92.22% rise in net profit at Rs 666.48 crore as compared to Rs 346.73 crore for the previous year. Total income of the company increased by 14.61% at Rs 5,905.38 crore for year under review as compared to Rs 5,152.54 crore for year ended March 31, 2023.

For the year ended March 31, 2024, on the consolidated basis, the company has reported 80.07% rise in its net profit at Rs 615.82 crore as compared to Rs 341.99 crore for the previous year. Total income of the company increased by 10.64% at Rs 6,256.93 crore for year under review as compared to Rs 5,655.36 crore for year ended March 31, 2023. 


Alembic Pharma Share Price

793.65 8.25 (1.05%)
11-May-2026 09:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1839.85
Dr. Reddys Lab 1293.00
Cipla 1340.75
Zydus Lifesciences 940.00
Lupin 2344.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×